MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) Short Interest Update

MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) was the recipient of a large increase in short interest in the month of April. As of April 15th, there was short interest totalling 393,000 shares, an increase of 260.2% from the March 31st total of 109,100 shares. Based on an average daily trading volume, of 219,000 shares, the short-interest ratio is presently 1.8 days. Approximately 20.6% of the company’s shares are sold short.

Hedge Funds Weigh In On MyMD Pharmaceuticals

An institutional investor recently raised its position in MyMD Pharmaceuticals stock. Cambria Investment Management L.P. increased its position in MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) by 184.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 171,570 shares of the company’s stock after buying an additional 111,335 shares during the period. Cambria Investment Management L.P. owned 0.38% of MyMD Pharmaceuticals worth $102,000 at the end of the most recent reporting period. 9.64% of the stock is currently owned by institutional investors and hedge funds.

MyMD Pharmaceuticals Stock Down 1.7 %

Shares of MYMD traded down $0.05 during trading hours on Thursday, reaching $2.81. The company’s stock had a trading volume of 20,266 shares, compared to its average volume of 188,870. The firm has a market cap of $6.07 million, a price-to-earnings ratio of -0.52 and a beta of 2.29. MyMD Pharmaceuticals has a 1-year low of $2.00 and a 1-year high of $70.50. The company has a 50 day moving average of $2.83 and a two-hundred day moving average of $6.32.

MyMD Pharmaceuticals Company Profile

MyMD Pharmaceuticals, Inc, a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the aging and age-related and autoimmune diseases, and chronic pain, anxiety, and sleep disorders. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system and its pro-inflammatory cytokines to prevent and treat autoimmune diseases and age-related illnesses, and a Phase 2 clinical trial for sarcopenia, multiple sclerosis, diabetes, inflammatory bowel diseases, and rheumatoid arthritis; inflammation related depression and anxiety; and COVID-19-associated depression.